Finally, a trial has been completed on different tumor types, including sarcoma, to investigate the safety and efficacy of Enapotamab Vedotin (HuMax-AXL-ADC), an AXL-specific antibody drug conjugate (NCT02988817). Here, AXL is linked to neoplasm.